23andMe Holding Co. (MEHCQ)
| Market Cap | 131.99M |
| Revenue (ttm) | 208.78M |
| Net Income (ttm) | -390.37M |
| Shares Out | 26.83M |
| EPS (ttm) | -15.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 407,968 |
| Average Volume | 653,234 |
| Open | 4.90 |
| Previous Close | 4.92 |
| Day's Range | 4.89 - 5.73 |
| 52-Week Range | 0.47 - 5.65 |
| Beta | 1.99 |
| RSI | 85.92 |
| Earnings Date | May 23, 2025 |
About 23andMe Holding Co.
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how... [Read more]
Financial Performance
In 2023, 23andMe Holding Co.'s revenue was $219.64 million, a decrease of -26.66% compared to the previous year's $299.49 million. Losses were -$666.70 million, 113.9% more than in 2022.
Financial StatementsNews
23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher
23andMe has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing company's former chief executive pushed a bankruptcy court to reopen it...
23andMe seeks new bids after $305 million offer from its co-founder
Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its assets, including customers' genetic data, after receiving a $305 million off...
23andMe customers notified of bankruptcy
23andMe has filed for Chapter 11 bankruptcy protection in the U.S., which means your genetic data is for sale, and you only have until July 14 to file a claim. This filing will initiate the sale of al...
23andMe founder aims to restart auction with major corporate backing
The founder of 23andMe , Anne Wojcicki, has asked a U.S. judge to reopen an auction for the genetic testing company, saying she has the support of a Fortune 500 company with a current market capitaliz...
23andMe to delist from Nasdaq, deregister with SEC
23andMe to delist from Nasdaq, deregister with SEC
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file...
What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy
Regeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitiv...
Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D, but the benefits are years away and the risks are immediate. Eylea franchise revenues dropped 26% year-over-year as biosi...
Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.
The rise and fall of 23andMe
A class action lawsuit, resignations, and layoffs plagued 23andMe, which filed for Chapter 11 in March. Biotech company Regeneron is buying the DNA testing startup's assets for $256 million.
Pharma giant Regeneron to buy 23andMe and its customers' data for $256M
Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction.
Bankrupt DNA testing firm 23andMe to be purchased for $256m
Drugmaker Regeneron Pharmaceuticals will buy the genetic testing firm through a bankruptcy auction
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
Regeneron Pharmaceuticals is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction. The drugmaker is buying 23andMe's Personal Genome Service, Total Health ...
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.
23andMe sells its most valuable asset. Regeneron promises keep your DNA private.
Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the th...
Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe's assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.
Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday.
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe's customer data; stands ready to work with independent, cour...
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
Regeneron Commits to Comply with Company's Privacy Policy and All Applicable Law; No Changes to 23andMe's Privacy Policy or Consumer Genome Services
23andMe will have court-appointed overseer for genetic data in bankruptcy
Genetic testing company 23andMe agreed on Tuesday to allow a court-appointed overseer to take charge of ensuring customers' genetic data remains protected during the company's bankruptcy, settling a d...
Congress has questions about 23andMe bankruptcy
3The leaders of the House Committee on Energy and Commerce said they are investigating how 23andMe's bankruptcy might affect customers' data.
23andMe Provides Update Regarding Court-Supervised Sale Process
SAN FRANCISCO, April 18, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today provided additional informati...
23andMe bankruptcy under congressional investigation for customer data
The House Committee on Energy and Commerce sent a letter to 23andMe expressing concern that its genetic data is "at risk of being compromised." The embattled genetic testing company filed for Chapter ...
US House committee seeks testimony from 23andMe co-founder after bankruptcy
A U.S. House committee on Monday asked 23andMe's co-founder to testify next month as it launched an investigation into the risk of genetic data being transferred to potential buyers amid the DNA testi...
23andMe probe launched to prevent customer DNA data from being sold to China or other bad actors
Sen. Bill Cassidy is probing 23andMe, which recently filed for bankruptcy protection, to ensure the company does not sell customer data to China or other foreign adversaries.